Fig. 2

RHM exerts anti-MM in vitro. A. Indicated MM cells were treated with increasing dose of RHM. CTG assay was performed 5 days from treatment. B. Immunoblot of LIG3 performed on plasmacells from MM cell lines. GAPDH was used as a loading control. C. Basal Alt-NHEJ repair of indicated MM cell lines. U266 repair activity was used as internal reference. D. Annexin V assay on AMO1 and H929 cells 4 days from RHM treatment (5 μM). E. Colony formation of H929 cells treated with vehicle or increasing dose of RHM. Light microscopy after 2 weeks is shown. F. Cell viability of CD138 + cells from 3 different MM patients co-cultured with HS-5 stromal cells and treated with RHM 10 μM or vehicle. The assay was performed 5 days after treatment. G. Healthy donors’ PBMCs (n = 7) cells were treated with increasing dose of RHM. CTG assay was performed 5 days from treatment. Results are representative of three experiments, ± SD. *, P < 0.01